We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Hologic (HOLX) Q4 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Hologic (HOLX - Free Report) to post quarterly earnings of $1.10 per share in its upcoming report, which indicates a year-over-year increase of 8.9%. Revenues are expected to be $1.03 billion, up 4.7% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 1.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Hologic metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts expect 'Revenues- GYN surgical' to come in at $175.86 million. The estimate suggests a change of +12.4% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Diagnostics- Molecular diagnostics' of $326.94 million. The estimate suggests a change of +2.4% year over year.
The average prediction of analysts places 'Revenues- Diagnostics- Blood screening' at $4.99 million. The estimate indicates a year-over-year change of -33.5%.
The consensus estimate for 'Revenues- Breast health- Breast imaging' stands at $286.03 million. The estimate indicates a change of -2.5% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Total Diagnostics' reaching $448.39 million. The estimate indicates a year-over-year change of +1.2%.
Analysts predict that the 'Revenues- Skeletal health' will reach $29.61 million. The estimate suggests a change of +133.2% year over year.
Analysts forecast 'Revenues- Diagnostics- Cytology and perinatal' to reach $116.46 million. The estimate suggests a change of 0% year over year.
Based on the collective assessment of analysts, 'Revenues- Total Breast health' should arrive at $379.38 million. The estimate indicates a year-over-year change of +1%.
According to the collective judgment of analysts, 'Revenues- Breast health- Interventional breast solutions' should come in at $93.35 million. The estimate suggests a change of +13.7% year over year.
The consensus among analysts is that 'Revenues- Service and other' will reach $206.32 million. The estimate indicates a year-over-year change of +3.1%.
It is projected by analysts that the 'Revenues- Product' will reach $825.89 million. The estimate points to a change of +4.8% from the year-ago quarter.
Over the past month, Hologic shares have recorded returns of +9.7% versus the Zacks S&P 500 composite's +3.8% change. Based on its Zacks Rank #3 (Hold), HOLX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gear Up for Hologic (HOLX) Q4 Earnings: Wall Street Estimates for Key Metrics
Wall Street analysts expect Hologic (HOLX - Free Report) to post quarterly earnings of $1.10 per share in its upcoming report, which indicates a year-over-year increase of 8.9%. Revenues are expected to be $1.03 billion, up 4.7% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 1.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Hologic metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts expect 'Revenues- GYN surgical' to come in at $175.86 million. The estimate suggests a change of +12.4% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Diagnostics- Molecular diagnostics' of $326.94 million. The estimate suggests a change of +2.4% year over year.
The average prediction of analysts places 'Revenues- Diagnostics- Blood screening' at $4.99 million. The estimate indicates a year-over-year change of -33.5%.
The consensus estimate for 'Revenues- Breast health- Breast imaging' stands at $286.03 million. The estimate indicates a change of -2.5% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Total Diagnostics' reaching $448.39 million. The estimate indicates a year-over-year change of +1.2%.
Analysts predict that the 'Revenues- Skeletal health' will reach $29.61 million. The estimate suggests a change of +133.2% year over year.
Analysts forecast 'Revenues- Diagnostics- Cytology and perinatal' to reach $116.46 million. The estimate suggests a change of 0% year over year.
Based on the collective assessment of analysts, 'Revenues- Total Breast health' should arrive at $379.38 million. The estimate indicates a year-over-year change of +1%.
According to the collective judgment of analysts, 'Revenues- Breast health- Interventional breast solutions' should come in at $93.35 million. The estimate suggests a change of +13.7% year over year.
The consensus among analysts is that 'Revenues- Service and other' will reach $206.32 million. The estimate indicates a year-over-year change of +3.1%.
It is projected by analysts that the 'Revenues- Product' will reach $825.89 million. The estimate points to a change of +4.8% from the year-ago quarter.
View all Key Company Metrics for Hologic here>>>Over the past month, Hologic shares have recorded returns of +9.7% versus the Zacks S&P 500 composite's +3.8% change. Based on its Zacks Rank #3 (Hold), HOLX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .